
Opinion|Videos|January 3, 2025
Treat-and-Extend Strategy With Aflibercept
Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What has been your experience using the treat-and-extend strategy with aflibercept 2 mg?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
2
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
3
FLORetina 2025: New horizons in research and risk management for ROP
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5














































